Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 15/20 | 0.56 |
| ▸ | CTSS | P25774 | 8/20 | 0.56 |
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624329 | 0.95 | CTSL (0.52) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624358 | 0.95 | CTSL (0.52) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624331 | 0.91 | CTSL (0.49) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL4369729 | 0.91 | CTSL (0.48) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624328 | 0.88 | CTSL (0.58) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624287 | 0.88 | CTSK (0.52) | CTSLCTSSCTSKCTSB | |
| SCHEMBL13624334 | 0.86 | CTSL (0.51) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL4369719 | 0.86 | CTSL (0.44) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL4370766 | 0.86 | CTSL (0.46) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL13624347 | 0.86 | CTSK (0.50) | CTSLCTSSCTSKCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSL 24/4885CTSS 5/4885CTSK 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.